IGF2 and cancer: To better define the metabolic effect of IR-A, which is the receptor principally involved in IGF2 action in cancer cells, we used MCF7 cells where the IGF1R was stably knocked-out by CRISPR/Cas technology and stably overexpressed the IR-A (MCF7IGF1R-ve/IR-A).